Literature DB >> 35610995

Efficacy and Safety of Mirikizumab as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Study.

.   

Abstract

Entities:  

Year:  2022        PMID： 35610995      PMCID： PMC9122067     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  2 in total

1.  Efficacy and Safety of Mirikizumab as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Study.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-04

2.  Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.

Authors:  William J Sandborn; Marc Ferrante; Bal R Bhandari; Elina Berliba; Brian G Feagan; Toshifumi Hibi; Jay L Tuttle; Paul Klekotka; Stuart Friedrich; Michael Durante; MaryAnn Morgan-Cox; Janelle Laskowski; Jochen Schmitz; Geert R D'Haens
Journal:  Gastroenterology       Date:  2019-09-04       Impact factor: 22.682
  2 in total
  2 in total

1.  Highlights in Ulcerative Colitis From the 17th Congress of the European Crohn's and Colitis Organisation: Commentary.

Authors:  David T Rubin
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-04

2.  Efficacy and Safety of Mirikizumab as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Study.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.